Dianthus Therapeutics logo

Dianthus TherapeuticsNASDAQ: DNTH

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 June 2018

Website:

http://dianthustx.com

Next earnings report:

30 August 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$721.12 M
-24%vs. 3y high
72%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

1.93
-57%vs. 3y high
56%vs. sector

PS ratio

319.79
-24%vs. 3y high
97%vs. sector

Price

regular market | 5 min ago
$24.57-$0.35(-1.40%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$0.54-$0.54

Revenue

Revenue target

$874.00 K$310.00 K

Revenue

Net income

$874.00 K-$13.75 M

Analysts recommendations

Total assets

Total liabilities

$382.46 M$9.78 M

Institutional Ownership

Included in screeners

Small cap companies
Worst performing stocks today
Stocks with low beta
Stocks with price above SMA 50
Price lower than analysts target
Analysts recommendations: buy
Stocks with high Altman Z score

Similar companies

89bio logo

89bio (ETNB)

Inhibrx logo

Inhibrx (INBX)

Immunome logo

Immunome (IMNM)

Cytek Biosciences logo

Cytek Biosciences (CTKB)

Harrow Health logo

Harrow Health (HROW)

Embecta logo

Embecta (EMBC)

HilleVax logo

HilleVax (HLVX)

CareDx logo

CareDx (CDNA)

DNTH Latest News

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
globenewswire.com28 June 2024 Sentiment: -

NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.

What type of business is Dianthus Therapeutics?

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

What sector is Dianthus Therapeutics in?

Dianthus Therapeutics is in the Healthcare sector

What industry is Dianthus Therapeutics in?

Dianthus Therapeutics is in the Biotechnology industry

What country is Dianthus Therapeutics from?

Dianthus Therapeutics is headquartered in United States

When did Dianthus Therapeutics go public?

Dianthus Therapeutics initial public offering (IPO) was on 21 June 2018

What is Dianthus Therapeutics website?

https://dianthustx.com

Is Dianthus Therapeutics in the S&P 500?

No, Dianthus Therapeutics is not included in the S&P 500 index

Is Dianthus Therapeutics in the NASDAQ 100?

No, Dianthus Therapeutics is not included in the NASDAQ 100 index

Is Dianthus Therapeutics in the Dow Jones?

No, Dianthus Therapeutics is not included in the Dow Jones index

When does Dianthus Therapeutics report earnings?

The next expected earnings date for Dianthus Therapeutics is 30 August 2024